MET and pachyonychia congenita: Moreover, MET phosphorylates PARP1 at pTyr907, which increases PARP1 enzyme activity and reduces the binding capacity of PARP inhibitors, resulting in drug resistance; while inhibition of MET enhances the antitumour effect of PARP inhibitors,18 but whether targeting MET also can improve the antitumour effect of PARP inhibitors in PC is currently unknown.